These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


246 related items for PubMed ID: 9458099

  • 1. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients.
    Narimatsu H, Iwasaki H, Nakayama F, Ikehara Y, Kudo T, Nishihara S, Sugano K, Okura H, Fujita S, Hirohashi S.
    Cancer Res; 1998 Feb 01; 58(3):512-8. PubMed ID: 9458099
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of urinary CA19-9 levels in bladder cancer patients classified according to the combinations of Lewis and Secretor blood group genotypes.
    Nagao K, Itoh Y, Fujita K, Fujime M.
    Int J Urol; 2007 Sep 01; 14(9):795-9. PubMed ID: 17760744
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Loss of Lewis antigen expression on erythrocytes in some cancer patients with high serum CA19-9 levels.
    Hirano K, Kawa S, Oguchi H, Kobayashi T, Yonekura H, Ogata H, Homma T.
    J Natl Cancer Inst; 1987 Dec 01; 79(6):1261-8. PubMed ID: 2447318
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Smoking and serum CA19-9 levels according to Lewis and secretor genotypes.
    Kawai S, Suzuki K, Nishio K, Ishida Y, Okada R, Goto Y, Naito M, Wakai K, Ito Y, Hamajima N.
    Int J Cancer; 2008 Dec 15; 123(12):2880-4. PubMed ID: 18803289
    [Abstract] [Full Text] [Related]

  • 12. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients.
    Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A, Yamaguchi H, Yasutake T, Ayabe H, Arisawa K.
    Hepatogastroenterology; 2003 Dec 15; 50(51):696-9. PubMed ID: 12828063
    [Abstract] [Full Text] [Related]

  • 13. Clinical evaluation of serum and immunohistochemical expression of SCC and CA19-9 in radiation therapy for cervical cancer.
    Abe A, Nakano T, Morita S, Oka K.
    Anticancer Res; 1999 Dec 15; 19(1B):829-36. PubMed ID: 10216501
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Expression of carbohydrate antigens (SSEA-1, sialyl-Lewis X, DU-PAN-2 and CA19-9) and E-selectin in urothelial carcinoma of the renal pelvis, ureter, and urinary bladder.
    Kajiwara H, Yasuda M, Kumaki N, Shibayama T, Osamura Y.
    Tokai J Exp Clin Med; 2005 Sep 15; 30(3):177-82. PubMed ID: 16285609
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 13.